Your browser doesn't support javascript.
loading
Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.
Humphries, Romney M; Ferraro, Mary Jane; Hindler, Janet A.
Afiliação
  • Humphries RM; Accelerate Diagnostics, Tucson, Arizona, USA rhumphries@axdx.com.
  • Ferraro MJ; Departments of Medicine and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Hindler JA; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA.
J Clin Microbiol ; 56(5)2018 05.
Article em En | MEDLINE | ID: mdl-29436415
ABSTRACT
Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Sensibilidade Microbiana / Testes Diagnósticos de Rotina / Política de Saúde / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Sensibilidade Microbiana / Testes Diagnósticos de Rotina / Política de Saúde / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article